Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40364
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLourens, Shantaily-
dc.contributor.authorVan Deun, Laura-
dc.contributor.authorPeeters, Ilse-
dc.contributor.authorPaemeleire, Koen-
dc.contributor.authorVan Dycke, Annelies-
dc.contributor.authorDE KLIPPEL, Nina-
dc.contributor.authorSchoenen, Jean-
dc.contributor.authorRitter, Shannon-
dc.contributor.authorSnellman, Josefin-
dc.contributor.authorVersijpt, Jan-
dc.date.accessioned2023-06-12T09:37:50Z-
dc.date.available2023-06-12T09:37:50Z-
dc.date.issued2023-
dc.date.submitted2023-06-08T14:17:53Z-
dc.identifier.citationActa neurologica belgica, 123 (4), p. 1495-1503-
dc.identifier.urihttp://hdl.handle.net/1942/40364-
dc.description.abstractIntroductionMigraine is a primary headache disorder, which imposes a major burden on the sufferers. The BECOME study (Burden of migrainE in specialist headache Centers treating patients with prOphylactic treatMent failurE) attempted to characterize and assess the prevalence, burden and healthcare resource utilization of migraine patients presenting in specialized headache centers in Europe and Israel. In this paper, we will describe the patient characteristics of the Belgian headache centers.MethodsThe BECOME study was a prospective, non-interventional, cross-sectional study consisting of two parts. In the first part of the study, data were collected from subjects with a diagnosis of migraine. Subsequently, patients with >= 4 monthly migraine days (MMD) and >= 1 prior preventive treatment failure (PPTF) filled out validated questionnaires to assess the burden of disease.ResultsIn part 1 of the Belgian study population (N = 806), 45% of patients reported >= 8 MMD and 25% had failed >= 4 preventive treatments. In part 2 (N = 90), more than 90% of patients reported having severe impact of headache on daily life and having severe migraine-related disability. The impact was the highest for patients with >= 15 MMD, however, even within the patient population with < 8 MMD, the burden was significant. Almost 40% of the study population suffered from anxiety.ConclusionsThese findings in the Belgian sample of the BECOME study demonstrate the substantial burden and unmet need for the management of difficult-to-treat migraine.-
dc.description.sponsorshipWe thank the BECOME steering committee, who were instrumental in protocol development. Members of the committee: Patricia Pozo-Rosich, Christian Lucas, David P. B. Watson, Charly Gaul, Emma Ramsden and Paolo Martelletti. Principal investigator: P. Pozo-Rosich, Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain. Funding This study was funded by Novartis Pharma AG, Basel, Switzerland. The study sponsor participated in the study design, data collection, data review, data analysis and writing of the report.-
dc.language.isoen-
dc.publisherSPRINGER HEIDELBERG-
dc.rightsThe Author(s) under exclusive licence to Belgian Neurological Society 2023-
dc.subject.otherBurden-
dc.subject.otherMigraine-
dc.subject.otherPatient-reported outcomes-
dc.subject.otherTreatment failure-
dc.titleBurden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study-
dc.typeJournal Contribution-
dc.identifier.epage1503-
dc.identifier.issue4-
dc.identifier.spage1495-
dc.identifier.volume123-
local.format.pages9-
local.bibliographicCitation.jcatA1-
dc.description.notesLourens, S (corresponding author), Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Neurol, Laarbeeklaan 101, B-1090 Brussels, Belgium.-
dc.description.notess.d.lourens@live.nl-
local.publisher.placeTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1007/s13760-023-02280-4-
dc.identifier.pmid37209257-
dc.identifier.isi000993020900002-
local.provider.typewosris-
local.description.affiliation[Lourens, Shantaily; Van Deun, Laura; Peeters, Ilse; Versijpt, Jan] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Neurol, Laarbeeklaan 101, B-1090 Brussels, Belgium.-
local.description.affiliation[Paemeleire, Koen] Ghent Univ Hosp, Dept Neurol, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.-
local.description.affiliation[Van Dycke, Annelies] Gen Hosp St Jan Bruges, Dept Neurol, Ruddershove 10, B-8000 Brugge, Belgium.-
local.description.affiliation[De Klippel, Nina] Jessa Ziekenhuis, Dept Neurol, Stadsomvaart 11, B-3500 Hasselt, Belgium.-
local.description.affiliation[Schoenen, Jean] Univ Liege, Citadelle Hosp, Dept Neurol, Headache Res Unit, Blvd 12 Eme Ligne 1, B-4000 Liege, Belgium.-
local.description.affiliation[Ritter, Shannon; Snellman, Josefin] Novartis Pharmaceut, E Hanover, NJ USA.-
local.description.affiliation[Ritter, Shannon; Snellman, Josefin] Novartis Pharm AG, Basel, Switzerland.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.fullcitationLourens, Shantaily; Van Deun, Laura; Peeters, Ilse; Paemeleire, Koen; Van Dycke, Annelies; DE KLIPPEL, Nina; Schoenen, Jean; Ritter, Shannon; Snellman, Josefin & Versijpt, Jan (2023) Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study. In: Acta neurologica belgica, 123 (4), p. 1495-1503.-
item.accessRightsRestricted Access-
item.contributorLourens, Shantaily-
item.contributorVan Deun, Laura-
item.contributorPeeters, Ilse-
item.contributorPaemeleire, Koen-
item.contributorVan Dycke, Annelies-
item.contributorDE KLIPPEL, Nina-
item.contributorSchoenen, Jean-
item.contributorRitter, Shannon-
item.contributorSnellman, Josefin-
item.contributorVersijpt, Jan-
crisitem.journal.issn0300-9009-
crisitem.journal.eissn2240-2993-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s13760-023-02280-4.pdf
  Restricted Access
Published version581.19 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.